Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2006 Jun;65(6):701-3.
doi: 10.1136/ard.2005.049890.

Differential drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis

P I Sidiropoulos, D T Boumpas
Editorial

Differential drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis

P I Sidiropoulos et al. Ann Rheum Dis. 2006 Jun.

Abstract

A significant number of patients receiving infliximab require dosing adjustments while some patients may indeed develop drug resistance

PubMed Disclaimer

Comment on

References

    1. Lipsky P E, van der Heijde D M, St Clair E W, Furst D E, Breedveld F C, Kalden J R.et al Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti‐Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 20003431594–1602. - PubMed
    1. Klareskog L, van der Heijde D, de Jager J P, Gough A, Kalden J, Malaise M.et al Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double‐blind randomised controlled trial. Lancet 2004363675–681. - PubMed
    1. Keystone E C, Kavanaugh A F, Sharp J T, Tannenbaum H, Hua Y, Teoh L S.et al Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti‐tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo‐controlled, 52‐week trial. Arthritis Rheum 2004501400–1411. - PubMed
    1. Sidiropoulos P, Bertsias G, Kritikos H D, Kouroumali H, Voudouris K, Boumpas D T. Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit. Ann Rheum Dis 200463144–148. - PMC - PubMed
    1. Finckh A, Simard J F, Gabay C, Guerne P ‐ A, for the SCQM physicians Evidence for differential acquired drug resistance to anti‐tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 200665746–752. - PMC - PubMed

MeSH terms